Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alimera Sciences Inc 6310 TOWN SQUARE SUITE 400 ALPHARETTA GA 30005 USA

www.alimerasciences.com P: 678-990-5740 F: 678-990-5744

Description:

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

Key Statistics

Overview:

Market Capitalization, $K 187,427
Enterprise Value, $K 239,827
Shares Outstanding, K 52,354
Annual Sales, $ 80,750 K
Annual Net Income, $ -20,130 K
Last Quarter Sales, $ 26,310 K
Last Quarter Net Income, $ -3,780 K
EBIT, $ 6,810 K
EBITDA, $ 16,580 K
60-Month Beta 1.18
% of Insider Shareholders 31.40%
% of Institutional Shareholders 99.83%
Float, K 35,915
% Float 68.60%
Short Volume Ratio 0.54

Growth:

1-Year Return 70.67%
3-Year Return -66.82%
5-Year Return -75.94%
5-Year Revenue Growth 71.92%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 03/07/24
Latest Earnings Date 05/20/24
Earnings Per Share ttm -1.28
EPS Growth vs. Prev Qtr -16.67%
EPS Growth vs. Prev Year 87.04%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 11/15/19

ALIM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 117.33
Price/Earnings to Growth N/A
Return-on-Equity % -130.90%
Return-on-Assets % -10.22%
Profit Margin % -24.93%
Debt/Equity 1.40
Price/Sales 2.30
Price/Cash Flow N/A
Price/Book 4.00
Book Value/Share 0.88
Interest Coverage -0.97
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar